<DOC>
	<DOCNO>NCT02583464</DOCNO>
	<brief_summary>Objective : To evaluate relative bioavailability new formulation contain combination emtricitabine 200 mg tenofovir disoproxil fumarate 300 mg ( T ) compare formulation brand formulation ( R ) meet regulatory criterion market test product Argentina .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations With Association Tenofovir 300 mg Emtricitabine 200 mg .</brief_title>
	<detailed_description>A randomized-sequence , open-label , two-period crossover study conduct 24 healthy Caucasian volunteer fast state . A single oral dose either T R formulation follow 7-day washout period . Blood sample collect baseline 0.25 , 0.50 , 0.75 , 1 , 1.25 , 1.5 2 , 2.5 , 3 , 4 , 7 , 12 , 24 48 h administration . Emtricitabine tenofovir concentration determine use validate LC ( liquid chromatography ) - MS ( mass spectrometry ) / MS method . Adverse event monitor base clinical parameter volunteer report .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>1 . Subjects sex 21 55 year . 2 . Subjects body mass index ( BMI ) 19 27 kg / mÂ² . 3 . Subjects whose complementary test ( ECG , blood urine ) within normal / clinically insignificant accord judgment investigator . Women childbearing age negative pregnancy test use reliable method contraception study ( IUD condom ) 4 . Subjects systolic blood pressure 110 mmHg 139 mmHg ; diastolic pressure 70 mmHg 89 mmHg ; heart rate 50 90 beat per minute . 5 . Subjects sign informed consent . 1 . Background clinically significant allergy ( except untreated asymptomatic seasonal allergy ) , drug hypersensitivity / hypersensitivity component formulation study . 2 . Drop 20 mmHg systolic blood pressure 10 mmHg diastolic pressure first 3 minute postural change . 3 . Active smoker 10 cigarette / day . 4 . Pregnant lactating woman . 5 . Current clinical evidence severe digestive disorder , surgery digestive tract ( except appendectomy ) . 6 . Current clinical evidence kidney disease . 7 . Current evidence liver disorder 8 . Current clinical evidence respiratory heart disease . 9 . The presence diabetes mellitus , thyroid dysfunction endocrine disorder . 10 . Evidence gastroduodenal disease . 11 . Current presence malignancy . 12 . History abuse addiction drug alcohol past three year . 13 . Participation clinical trial within last three month . 14 . Use drug within fourteen day start study . 15 . Subject donate suffered blood loss last twelve week start study , intend donate blood within three month completion study . 16 . Excessive drinking tea , cocoa , mate , coffee / beverage contain caffeine ( &gt; 5 cup / day ) wine ( &gt; 0.5 L / day ) alcohol ( &gt; 50 ml / day ) . 17 . ECG abnormality . 18 . Positive serology HIV , hepatitis B hepatitis C. 19 . Women use effective contraception ( IUD , condom )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>